FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations may
continue. See
Instruction 1(b)

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Instruction 1(b). Company Act of 1940

(Print or Type Responses)												
1. Name and Address of Re Amado Rafael		2. Issuer Name <b>and</b> Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner				
(Last) 5 ASHWOOD LANE	(First)		3. Date of Earliest Transaction (Month/Day/Year) 01/04/2019					_X_Officer (give title below)Other (specify below) President, R & D				
(Street) MALVERN, PA 19355			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1. Title of Security     2. Transaction       (Instr. 3)     Date       (Month/Day/Yet)				3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s)		Beneficial	
			(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	x ,	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative	2. Conversion		3A. Deemed Execution Date, if	4. Transact	tion	5. Number of Derivative		<ol> <li>Date Exer Expiration I</li> </ol>		7. Title and Underlying		8. Price of Derivative		10. Ownership	11. Nature of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Securities		•		Underlying Securities (Instr. 3 and 4)		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of Derivative		(Month/Day/Year)	(Instr. 8)	)	Acquired (A) or Disposed of (D)					(Instr. 5)	Beneficially Owned	Derivative Security:	Ownership (Instr. 4)	
	Security					(Instr. 3, 4, a						Following	Direct (D) or Indirect	× /	
						5)			Amount or			Transaction(s)	(I)		
				Code	v		(D)	Date Exercisable	Expiration Date	Title	Number of Shares		(Instr. 4)	(Instr. 4)	
				Code	v	(A)	(D)				Shares				
Option															
to purchase	\$ 0.89 (1)	01/04/2019		А		1,006,224		(2)	01/04/2029	Ordinary	1,006,224	\$ 0	1,006,224	D	
Ordinary		01/01/2019		11		1,000,221			01/01/2029	Shares	1,000,221	ψŪ	1,000,221	D	
Shares															
Option															
to	\$ 0.0013	01/04/2010				224 724		<u>(4)</u>	(5)	Ordinary	224 724	¢.0	224 724	P	
purchase Ordinary	(3)	01/04/2019		А		224,724		<u>(4)</u>	<u>1</u>	Shares	224,724	\$ 0	224,724	D	
Shares															

## **Reporting Owners**

	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Amado Rafael 5 ASHWOOD LANE MALVERN, PA 19355			President, R & D						

# Signatures

/s/ Rafael Amado	01/08/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The exercise price was converted from GBP0.70 based on an exchange rate of \$U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount.

- Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from (2) February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023.
- (3) The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.26332 GBP1.00. The actual exercise price will be the pounds sterling amount.
- (4) Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023.
- (5) The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.